Intervention not reported
Total number of adverse events · children with chronic asthma
The intervention showed no clear difference in total number of adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Number of participants with exacerbations requiring hospitalisation · children with chronic asthma
The intervention showed no clear difference in number of participants with exacerbations requiring hospitalisation (moderate certainty).
1 finding from 1 review
Death at hospital discharge · neonates with clinical and microbiological features of bacterial meningitis
It is very uncertain whether adjunctive steroid changes all‐cause death until hospital discharge compared with placebo (very low certainty).
1 finding from 1 review
Developmental delay at ≥ 18 months · neonates with clinical and microbiological features of bacterial meningitis
Adjunctive steroid showed no clear difference in number of participants with developmental delay compared with placebo (low certainty).
1 finding from 1 review
Hearing loss · neonates with clinical and microbiological features of bacterial meningitis
Adjunctive steroid showed no clear difference in hearing loss at 2 years of age compared with placebo (low certainty).
2 findings from 1 review
Intervention not reported
Pain at 1 week Scale from: 0 to 10 · adult patients with cancer‐related pain
1 finding from 1 review
Asthma control · adults with asthma well controlled on LABA and ICS
1 finding from 1 review
Serious adverse events 17 weeks · adults with asthma well controlled on LABA and ICS
Stopping LABA showed no clear difference in serious adverse events 17 weeks compared with continuing use of LABA+ICS (moderate certainty).
1 finding from 1 review
Asthma‐related quality of life (MCID) · adults with asthma well controlled on LABA and ICS
1 finding from 1 review
Exacerbation: hospital 17 weeks · adults with asthma well controlled on LABA and ICS
1 finding from 1 review
Adverse events (all) · adults with asthma well controlled on LABA and ICS
Stopping LABA showed no clear difference in adverse events (all) compared with continuing use of LABA+ICS (moderate certainty).
1 finding from 1 review
Withdrawal (all‐cause) · adults with asthma well controlled on LABA and ICS
Stopping LABA probably leads to higher withdrawal (all) compared with continuing use of LABA+ICS (moderate certainty).
1 finding from 1 review
Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · adults with asthma not well controlled on ICS
1 finding from 1 review
All‐cause serious adverse events 24 weeks · adults with asthma not well controlled on ICS
LAMA add‐on showed no clear difference in all‐cause serious adverse events 24 weeks compared with ICS alone (low certainty).
1 finding from 1 review
Hospital admission (exacerbation) · adults with asthma not well controlled on ICS
LAMA add‐on showed no clear difference in exacerbations requiring hospital admission 24 weeks compared with ICS alone (moderate certainty).
1 finding from 1 review
Change in baseline trough FEV1 · adults with asthma not well controlled on ICS
1 finding from 1 review
Asthma control · adults with asthma not well controlled on ICS
1 finding from 1 review
Any adverse events 24 weeks · adults with asthma not well controlled on ICS
LAMA add‐on showed no clear difference in any adverse events 24 weeks compared with ICS alone (low certainty).
1 finding from 1 review
Mean exacerbations requiring a course of oral corticosteroids · adults with asthma
ICS + LAMA add‐on showed no clear difference in exacerbations requiring a course of OCSa 14 weeks compared with ICS dose increase (low certainty).
1 finding from 1 review
AQLQ score (Scale 1 to 7, where 1 = severely impaired and 7 = no impairment) · adults with asthma
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low